These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17414959)

  • 1. Update on cytokines in rheumatoid arthritis.
    Brennan F; Beech J
    Curr Opin Rheumatol; 2007 May; 19(3):296-301. PubMed ID: 17414959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging cytokine targets in rheumatoid arthritis.
    Asquith DL; McInnes IB
    Curr Opin Rheumatol; 2007 May; 19(3):246-51. PubMed ID: 17414950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of T cells in rheumatoid arthritis: new subsets and new targets.
    Toh ML; Miossec P
    Curr Opin Rheumatol; 2007 May; 19(3):284-8. PubMed ID: 17414957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages and their products in rheumatoid arthritis.
    Szekanecz Z; Koch AE
    Curr Opin Rheumatol; 2007 May; 19(3):289-95. PubMed ID: 17414958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.
    Sheibanie AF; Khayrullina T; Safadi FF; Ganea D
    Arthritis Rheum; 2007 Aug; 56(8):2608-19. PubMed ID: 17665454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines in rheumatoid arthritis: is it all TNF-alpha?
    Miossec P
    Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):675-8. PubMed ID: 11502074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?
    Lubberts E
    Cytokine; 2008 Feb; 41(2):84-91. PubMed ID: 18039580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines and their antagonists in the treatment of rheumatoid arthritis].
    Klimiuk PA; Sierakowski S
    Przegl Lek; 2002; 59(2):108-12. PubMed ID: 12152246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future trends in the treatment of rheumatoid arthritis: cytokine targets.
    Breedveld FC
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():11-3. PubMed ID: 10646483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.
    Andreakos E; Rauchhaus U; Stavropoulos A; Endert G; Wendisch V; Benahmed AS; Giaglis S; Karras J; Lee S; Gaus H; Bennett CF; Williams RO; Sideras P; Panzner S
    Arthritis Rheum; 2009 Apr; 60(4):994-1005. PubMed ID: 19333921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokines in rheumatoid arthritis. I. Proinflammatory cytokines].
    Klimiuk PA; Sierakowski S
    Pol Merkur Lekarski; 2001 Dec; 11(66):510-3. PubMed ID: 11899850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine networks--towards new therapies for rheumatoid arthritis.
    McInnes IB; Liew FY
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):31-9. PubMed ID: 16932625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
    Williams RO; Paleolog E; Feldmann M
    Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-17 and Th17 cells in rheumatoid arthritis.
    Sarkar S; Fox DA
    Rheum Dis Clin North Am; 2010 May; 36(2):345-66. PubMed ID: 20510238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental therapy of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Rheumatol; 1995; 54(2):105-9. PubMed ID: 7793156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.
    Rafei M; Berchiche YA; Birman E; Boivin MN; Young YK; Wu JH; Heveker N; Galipeau J
    J Immunol; 2009 Aug; 183(3):1759-66. PubMed ID: 19592643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.
    Ito Y; Usui T; Kobayashi S; Iguchi-Hashimoto M; Ito H; Yoshitomi H; Nakamura T; Shimizu M; Kawabata D; Yukawa N; Hashimoto M; Sakaguchi N; Sakaguchi S; Yoshifuji H; Nojima T; Ohmura K; Fujii T; Mimori T
    Arthritis Rheum; 2009 Aug; 60(8):2294-303. PubMed ID: 19644886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways.
    Amin MA; Mansfield PJ; Pakozdi A; Campbell PL; Ahmed S; Martinez RJ; Koch AE
    Arthritis Rheum; 2007 Jun; 56(6):1787-97. PubMed ID: 17530707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis.
    Hintzen C; Quaiser S; Pap T; Heinrich PC; Hermanns HM
    Arthritis Rheum; 2009 Jul; 60(7):1932-43. PubMed ID: 19565514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.